Moran's most recent trade in AlTi Global Inc - Ordinary Shares - Class A was a trade of 692,612 Restricted Stock Units done . Disclosure was reported to the exchange on June 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2025 | 692,612 | 692,612 | - | - | Restricted Stock Units | |
| BioAtla Inc | Susan Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 23,500 | 52,307 | - | 0 | Common Stock | |
| Sweetgreen Inc - Ordinary ... | Montgomery F. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 13,755 | 53,755 | - | 0 | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Jun 2025 | 28,509 | 60,311 | - | 3.5 | 98,927 | Class A Common Stock |
| Tyra Biosciences Inc | Susan Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 22,200 | 22,200 | - | - | Stock Option (Right to Buy) | |
| First United Corporation | Beth E. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 1,000 | 27,952 (0%) | 0% | 0 | Common Stock | |
| Manhattan Associates, Inc. | Charles E. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 1,330 | 22,138 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Susan E. Morano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 2,081 | 6,034 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Susan E. Morano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 605 | 6,639 (0%) | 0% | 0 | Common Stock | |
| Omega Flex Inc | Edwin B. Moran | Director, President | Purchase of securities on an exchange or from another person at price $ 29.72 per share. | 02 May 2025 | 500 | 500 (0%) | 0% | 29.7 | 14,860 | Common Stock |
| Kalaris Therapeutics Inc. | Morana Jovan-Embiricos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 106,464 | 106,464 | - | - | Restricted Stock Units | |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 11,552 | 108,351 (0%) | 0% | 0 | Common Stock | |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.96 per share. | 15 Mar 2025 | 5,686 | 103,951 (0%) | 0% | 21.0 | 119,179 | Common Stock |
| Dover | James M. Moran | VP & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 179.62 per share. | 14 Mar 2025 | 29 | 6,078 (0%) | 0% | 179.6 | 5,209 | Common Stock |
| Dover | James M. Moran | VP & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 179.61 per share. | 14 Mar 2025 | 28 | 6,050 (0%) | 0% | 179.6 | 5,029 | Common Stock |
| Dover | James M. Moran | VP & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 179.60 per share. | 14 Mar 2025 | 25 | 6,107 (0%) | 0% | 179.6 | 4,490 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 01 Mar 2025 | 26,941 | 328,822 (0%) | 0% | 4.8 | 128,239 | Common Stock |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 19,513 | 103,993 (0%) | 0% | 0 | Common Stock | |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.75 per share. | 01 Mar 2025 | 5,655 | 98,338 (0%) | 0% | 23.7 | 134,306 | Common Stock |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.75 per share. | 01 Mar 2025 | 1,539 | 96,799 (0%) | 0% | 23.7 | 36,551 | Common Stock |
| Astronics Corp. | Mark J. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 6,055 | 6,055 | - | - | Restricted Stock Unit | |
| Safety Insurance Group, Inc. | Mary Coffey Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 1,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Omega Flex Inc | Edwin B. Moran | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 2,069 | 2,069 | - | - | Phantom Stock | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Purchase of securities on an exchange or from another person at price $ 4.39 per share. | 21 Feb 2025 | 2,000 | 355,763 (0%) | 0% | 4.4 | 8,779 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 125,000 | 353,763 (0%) | 0% | 0 | Common Stock | |
| Hanesbrands Inc | Robert F. Moran | Director | Purchase of securities on an exchange or from another person at price $ 6.01 per share. | 18 Feb 2025 | 66,500 | 208,023 (0%) | 0% | 6.0 | 399,665 | Common Stock |
| Hanesbrands Inc | Robert F. Moran | Director | Purchase of securities on an exchange or from another person at price $ 6.02 per share. | 18 Feb 2025 | 8,350 | 216,373 (0%) | 0% | 6.0 | 50,234 | Common Stock |
| Omega Flex Inc | Edwin B. Moran | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 402 | 402 (0%) | 0% | - | Common Stock | |
| Omega Flex Inc | Edwin B. Moran | Director, President | Sale or transfer of securities back to the company at price $ 38.62 per share. | 18 Feb 2025 | 402 | 0 (0%) | 0% | 38.6 | 15,525 | Common Stock |
| Omega Flex Inc | Edwin B. Moran | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 402 | 0 | - | - | Phantom Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 47,397 | 47,397 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 47,397 | 75,034 | - | 0 | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,785 | 27,570 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,785 | 88,820 | - | 0 | Class A Common Stock | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 14 Feb 2025 | 2,792 | 73,313 (0%) | 0% | 8.8 | 24,446 | Common Stock, par value $0.0001 per share |
| Dover | James M. Moran | VP & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 1,977 | 1,977 | - | - | Stock Appreciation Right | |
| Dover | James M. Moran | VP & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 393 | 6,268 (0%) | 0% | 0 | Common Stock | |
| Dover | James M. Moran | VP & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 222 | 5,875 (0%) | 0% | 0 | Common Stock | |
| Dover | James M. Moran | VP & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 202.33 per share. | 14 Feb 2025 | 136 | 6,132 (0%) | 0% | 202.3 | 27,517 | Common Stock |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 252,000 | 252,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 42,000 | 89,218 (0%) | 0% | 0 | Ordinary Shares | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 92,500 | 92,500 | - | - | Stock options (right to buy) | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 27,500 | 76,105 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Hanesbrands Inc | Robert F. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 18,630 | 141,523 (0%) | 0% | 0 | Common Stock | |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Other type of transaction at price $ 20.61 per share. | 31 Dec 2024 | 303 | 84,480 (0%) | 0% | 20.6 | 6,246 | Common Stock |
| Hanesbrands Inc | F. Moran Robert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 9,520 | 122,893 (0%) | 0% | - | Common Stock | |
| Hanesbrands Inc | Robert Moran F. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 9,520 | 0 | - | - | Phantom Stock | |
| Intapp Inc | Charles E. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2024 | 3,817 | 25,826 | - | 0 | Common Stock | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 25,000 | 0 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 11 Oct 2024 | 25,000 | 44,777 (0%) | 0% | 2.5 | 62,000 | Ordinary Shares |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Other type of transaction at price $ 17.73 per share. | 30 Sep 2024 | 353 | 84,177 (0%) | 0% | 17.7 | 6,258 | Common Stock |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 25 Sep 2024 | 17,146 | 19,777 (0%) | 0% | 9 | 154,314 | Ordinary Shares |
| Old National Bancorp | John V. Moran | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 21,563 | 83,779 (0%) | 0% | 0 | Common Stock | |
| Astronics Corp. | Mark J. Moran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2024 | 6,346 | 0 | - | - | Restricted Stock Unit | |
| Astronics Corp. | Mark J. Moran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2024 | 6,346 | 36,468 (0%) | 0% | 0 | $.01 PV Com Stk | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 20 Aug 2024 | 137,500 | 27,637 | - | 4 | 550,000 | Class A Common Stock |
| Commvault Systems Inc | Charles E. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2024 | 1,530 | 12,497 (0%) | 0% | 0 | Common Stock | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 5.92 per share. | 29 Jul 2024 | 2,251 | 228,763 (0%) | 0% | 5.9 | 13,327 | Common Stock |
| Mobileye Global Inc - Ordi... | Rojansky Moran Shemesh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2024 | 54,565 | 119,337 | - | 0 | Class A Common Stock | |
| Old National Bancorp | John V. Moran | EVP, CHIEF STRATEGY OFFICER | Other type of transaction at price $ 16.33 per share. | 28 Jun 2024 | 383 | 62,216 (0%) | 0% | 16.3 | 6,255 | Common Stock |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 7,788 | 23,367 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 14 Jun 2024 | 7,788 | 48,605 (0%) | 0% | 49.9 | 388,417 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 7,788 | 56,393 (0%) | 0% | 4.3 | 33,177 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 6,730 | 11,217 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.77 per share. | 14 Jun 2024 | 6,730 | 48,605 (0%) | 0% | 46.8 | 314,789 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 6,730 | 55,335 (0%) | 0% | 14.1 | 94,893 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,958 | 0 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.12 per share. | 14 Jun 2024 | 1,958 | 48,605 (0%) | 0% | 42.1 | 82,479 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,958 | 50,563 (0%) | 0% | 30 | 58,740 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,567 | 50,172 (0%) | 0% | 30 | 47,010 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,567 | 1,958 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 14 Jun 2024 | 1,567 | 48,605 (0%) | 0% | 49.9 | 78,152 | Common Stock, par value $0.0001 per share |
| BioAtla Inc | Susan Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 16,500 | 28,807 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Morana Jovan-Embiricos | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 35,000 | 100,197 | - | 0 | Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 236,967 | 236,967 | - | - | Peformance Restricted Stock Unit | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 41,356 | 41,356 | - | - | Restricted Stock Units | |
| Arhaus Inc - Ordinary Shar... | John E. Moran | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 13,613 | 13,613 | - | - | Performance Share Units | |
| Arhaus Inc - Ordinary Shar... | John E. Moran | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 4,538 | 4,538 | - | - | Restricted Stock Units | |
| Commvault Systems Inc | Charles E. Moran | Director | Sale of securities on an exchange or to another person at price $ 110.83 per share. | 29 May 2024 | 11,000 | 10,967 (0%) | 0% | 110.8 | 1,219,130 | Common Stock |
| Manhattan Associates, Inc. | Charles E. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 1,154 | 20,808 (0%) | 0% | 0 | Common Stock | |
| First United Corporation | Beth E. Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,227 | 26,952 (0%) | 0% | 0 | Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Sale of securities on an exchange or to another person at price $ 4.70 per share. | 16 May 2024 | 10,047 | 165,137 | - | 4.7 | 47,221 | Class A Common Stock |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Sale of securities on an exchange or to another person at price $ 4.70 per share. | 14 May 2024 | 591 | 175,184 | - | 4.7 | 2,778 | Class A Common Stock |
| Boston Scientific | Susan E. Morano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 1,450 | 3,532 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Susan E. Morano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 1,450 | 3,532 | - | - | Deferred Stock Units | |
| Boston Scientific | Susan E. Morano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 421 | 3,953 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Susan E. Morano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 421 | 3,953 | - | - | Deferred Stock Units | |
| Tyra Biosciences Inc | Susan Moran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 37,200 | 37,200 | - | - | Common Stock (Right to Buy) | |
| Southwest Gas Holdings Inc | Thomas E. Moran | VP/General Counsel/Corp. Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 1,685 | 4,562 (0%) | 0% | 0 | Common Stock | |
| Southwest Gas Holdings Inc | Thomas E. Moran | VP/General Counsel/Corp. Sec | Grant, award, or other acquisition of securities at price $ 70.70 per share. | 02 May 2024 | 10 | 4,582 (0%) | 0% | 70.7 | 707 | Common Stock |
| Southwest Gas Holdings Inc | Thomas E. Moran | VP/General Counsel/Corp. Sec | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 02 May 2024 | 9 | 4,572 (0%) | 0% | 70.4 | 634 | Common Stock |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 1,787 | 0 | - | - | Employee Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 10 Apr 2024 | 1,787 | 48,605 (0%) | 0% | 30 | 53,610 | Common Stock |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.17 per share. | 03 Apr 2024 | 15,630 | 33,921 (0%) | 0% | 6.2 | 96,421 | Ordinary Shares |
| Vroom Inc. | Patricia Moran | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 12.24 per share. | 03 Apr 2024 | 58 | 10,787 | - | 12.2 | 710 | Common Stock |
| Dream Finders Homes Inc - ... | J. Douglas Moran | Senior VP and COO | 01 Apr 2024 | 13,927 | 527,979 | - | 42.9 | 597,329 | Class A common stock, par value $0.01 per share | |
| Old National Bancorp | John V. Moran | EVP, CHIEF STRATEGY OFFICER | Other type of transaction at price $ 16.54 per share. | 28 Mar 2024 | 378 | 61,782 (0%) | 0% | 16.5 | 6,252 | Common Stock |
| Omega Flex Inc | Edwin B. Moran | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 1,042 | 1,042 | - | - | Phantom Stock | |
| Dover | James M. Moran | VP & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 175.06 per share. | 15 Mar 2024 | 32 | 5,707 (0%) | 0% | 175.1 | 5,602 | Common Stock |
| Dover | James M. Moran | VP & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 175.07 per share. | 15 Mar 2024 | 29 | 5,653 (0%) | 0% | 175.1 | 5,077 | Common Stock |